Fermentation-based API and formulation maker for immunosuppressant, oncology and anti-infective drugs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 761 | 990 | 1.1k | 1.3k | 1.5k | 1.8k | 1.8k | 2.0k |
| Borrowings | 52 | 86 | 62 | 32 | 10 | 3 | 2 | 2 |
| Other Liabilities | 118 | 97 | 147 | 192 | 164 | 219 | 194 | 212 |
| Total Liabilities | 941 | 1.2k | 1.3k | 1.5k | 1.7k | 2.0k | 2.0k | 2.2k |
| AssetsFixed Assets | 240 | 546 | 573 | 593 | 575 | 795 | 795 | 789 |
| CWIP | 141 | 18 | 74 | 173 | 211 | 51 | 74 | 79 |
| Investments | 199 | 141 | 74 | 137 | 246 | 335 | 353 | 491 |
| Other Assets | 361 | 477 | 592 | 611 | 668 | 854 | 802 | 873 |
| Total Assets | 941 | 1.2k | 1.3k | 1.5k | 1.7k | 2.0k | 2.0k | 2.2k |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 155 | 167 | 207 | 246 | 265 | 245 | 267 |
| Cash from Investing | -114 | -195 | -112 | -158 | -155 | -160 | -143 |
| Cash from Financing | -43 | 31 | -100 | -85 | -99 | -99 | -113 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | -1 | -38 | 52 | 101 | 180 | 134 | 172 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (51.7×) and current (53.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 2.7% growth and a 52× exit, ₹1343 only delivers your return if you pay ₹616. The price is currently baking in 18% growth.
EPS grows 2.7%/yr for 5 years, then fades to 6% over 2, exits at 52×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 2.7% | 25.61 |
| FY28 | 2.7% | 26.30 |
| FY29 | 2.7% | 27.02 |
| FY30 | 2.7% | 27.74 |
| FY31 | 2.7% | 28.49 |
| FY32 | 4.3% ·fade | 29.73 |
| FY33 | 6.0% ·fade | 31.52 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.